On April 6, 2022, Cell Metabolism published new research co-authored by AFAR grantee Nicolas Musi, MD, which uses a liver enzyme inhibitor to increase mRNAs and reduce body weight in obese mice, showing improved insulin sensitivity and a potential approach to tackling metabolic diseases.
Dr. Musi is a 2007 Paul B. Beeson Emerging Leaders Career Development Award in Aging Scholar recipient. He is also the Director of the Sam and Ann Barshop Institute for Longevity and Aging Studies, the Director of the Center for Healthy Aging, the Director of the San Antonio Claude D. Pepper Older American Independence Center, the Associate Director for Research Programs at San Antonio Geriatric Research, Education, and Clinical Center (GRECC), and a Professor of Medicine at the University of Texas, San Antonio. He is also co-leader of the Integrated Physiology of Aging Core at the Nathan Shock Center at UT Health San Antonio, one of the NIA’s six Nathan Shock Centers of Excellence in the Basic Biology of Aging, for which AFAR serves as the Coordinating Center.
Read the research, “Deadenylase-dependent mRNA decay of GDF15 and FGF21 orchestrates food intake and energy expenditure,” here.
Read a related press release here.
